{"DataElement":{"publicId":"3244912","version":"1","preferredName":"Person Prior Clinical Study Agent Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to a person having had clinical study agent as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3244911v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3244911","version":"1","preferredName":"Person Prior Clinical Study Agent Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person having had clinical study agent as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3244909v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3244909","version":"1","preferredName":"Prior Clinical Study Agent Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order.:Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. :An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25629:C15206:C1708:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5C6317A-9255-CEBC-E040-BB89AD43192F","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"ONEDATA","dateModified":"2011-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5C6317A-9266-CEBC-E040-BB89AD43192F","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"3244911v1.0:2018257v1.0","type":"USED_BY","context":"CTEP"},{"name":"PrChxECIND","type":"COG GDE Short Name","context":"COG"},{"name":"3244911v1.0:2018257v1.0","type":"USED_BY","context":"COG"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"TEST","type":"USED_BY","context":"TEST"}],"ReferenceDocuments":[{"name":"Has patient previously receiv","type":"Preferred Question Text","description":"Has patient previously received any of the indicated agents","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Did the patient have prior chemotherapy or radiation therapy for this disease (excluding laser and cryotherapy)?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Did patient previously receive eribulin, halichondrin B or analogues of halichondrin B?","url":null,"context":"COG"},{"name":"COG CRF TEXT 3","type":"Alternate Question Text","description":"Did patient receive the indicated agent prior to start of protocol therapy?","url":null,"context":"COG"},{"name":"COG_CRF_TEXT_4","type":"Alternate Question Text","description":"Has patient received any of the indicated agents within 7 days of enrollment?","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Did patient previously receive denosumab?","url":null,"context":"CTEP"},{"name":"ALT - 1","type":"Alternate Question Text","description":"Has participant received any study therapies prior to registration?","url":null,"context":"ECOG-ACRIN"},{"name":"COG_CRF_TEXT_6","type":"Alternate Question Text","description":"Did patient previously receive mithramycin, strontium 89, samarium-153 or rhenium?","url":null,"context":"CTEP"},{"name":"COG CRF Text 10","type":"Alternate Question Text","description":"Did patient receive CPX-351 during this reporting period?","url":null,"context":"CTEP"},{"name":"COG CRF Text 8","type":"Alternate Question Text","description":"Has patient not received prior re-induction therapy?","url":null,"context":"CTEP"},{"name":"COG CRF Text 9","type":"Alternate Question Text","description":"Has patient received > 450 mg/mÂ² daunorubicin equivalents?","url":null,"context":"CTEP"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Has patient received prior treatment with eribulin?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_11","type":"Alternate Question Text","description":"Has patient received greater than or equal to 450 mg/m2 daunorubicin equivalents","url":null,"context":"COG"},{"name":"NRG CRF_Text12","type":"Alternate Question Text","description":"Has the patient received treatment with a P13K inhibitor within 30 days prior to registration?","url":null,"context":"NRG"},{"name":"COG_CRF_TEXT_3","type":"Alternate Question Text","description":"Patient previously received agent","url":null,"context":"COG"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"Did patient receive Course LMP-TC1 during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 11","type":"Alternate Question Text","description":"Did patient receive Course LMP-TC2 during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 14","type":"Alternate Question Text","description":"Did patient receive Course RTX2 during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"Did patient receive Course RTX1 during this reporting period?","url":null,"context":"COG"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Has the patient received 1 cycle of chemotherapy treatment prior to registration/randomization?","url":null,"context":"Alliance"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Did the patient have Cycle 1 of FOLFOX6 prior to registration?","url":null,"context":"Alliance"},{"name":"COG CRF TEXT 12","type":"Alternate Question Text","description":"Has patient received prior therapy with axitinib or nivolumab or other VEGF or PD1/PDL1 targeted therapies?","url":null,"context":"COG"},{"name":"COG CRF Text 15","type":"Alternate Question Text","description":"Did patient receive Course RTX during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Has patient previously received any of the indicated agents?","url":null,"context":"COG"},{"name":"COG CRF TEXT 16","type":"Alternate Question Text","description":"Did patient receive Gilteritinib during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 17","type":"Alternate Question Text","description":"Has patient received prior therapy with axitinib?","url":null,"context":"COG"},{"name":"COG CRF Text 18","type":"Alternate Question Text","description":"Has the patient received denosumab within the indicated period?","url":null,"context":"COG"},{"name":"COG CRF Text 19","type":"Alternate Question Text","description":"Did patient receive CPX-351 during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF TEXT 21","type":"Alternate Question Text","description":"Was day 1 of IMGN632 administered?","url":null,"context":"COG"},{"name":"COG CRF TEXT 20","type":"Alternate Question Text","description":"Did patient receive any IMGN632 during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF TEXT 22","type":"Alternate Question Text","description":"Was day 22 of IMGN632 administered?","url":null,"context":"COG"},{"name":"COG CRF Text 23","type":"Alternate Question Text","description":"'Was day 1 of IMGN632 administered?","url":null,"context":"COG"},{"name":"COG CRF Text 24","type":"Alternate Question Text","description":"Was day 22 of IMGN632 administered?","url":null,"context":"COG"},{"name":"COG CRF Text 25","type":"Alternate Question Text","description":"Has patient previously been treated with SNDX-5613?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A5C6317A-9282-CEBC-E040-BB89AD43192F","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"2023.3.6 AQT added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"}}